Scarica l'app Stockscreener
1.88
8.05%
0.14
Dopo l'orario di chiusura:
1.79
-0.09
-4.79%
Precedente Chiudi:
$1.74
Aprire:
$1.71
Volume 24 ore:
44,051
Relative Volume:
0.85
Capitalizzazione di mercato:
$6.00M
Reddito:
-
Utile/perdita netta:
$-29.77M
Rapporto P/E:
-0.1229
EPS:
-15.2954
Flusso di cassa netto:
$-24.23M
1 W Prestazione:
+14.63%
1M Prestazione:
+1.08%
6M Prestazione:
-57.61%
1 anno Prestazione:
-79.79%
Intervallo 1D:
$1.71
$1.9279
Intervallo di 1 settimana:
$1.60
$1.99
Portata 52W:
$1.50
$10.35
Moleculin Biotech Inc Stock (MBRX) Company Profile
Nome
Moleculin Biotech Inc
Settore
Industria
Telefono
713-300-5160
Indirizzo
5300 MEMORIAL DRIVE, HOUSTON, TX
Confronta MBRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
1.88 | 6.00M | 0 | -29.77M | -24.23M | -15.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-07-18 | Ripresa | Oppenheimer | Outperform |
Moleculin Biotech Inc Borsa (MBRX) Ultime notizie
StockNews.com Begins Coverage on Moleculin Biotech (NASDAQ:MBRX) - Defense World
What is Roth Capital’s Estimate for MBRX FY2029 Earnings? - Defense World
Moleculin Biotech Issues Positive Business Outlook and Expected Milestones in Recent Press Release On January 8, 2025, Moleculin Biotech, Inc. (NASDAQ: MBRX) released a press release highlighting its business outlook and anticipated upcoming milesto - Defense World
Moleculin Biotech (NASDAQ:MBRX) Corporate Presentation Available OnlineOn January 8, 2025, Moleculin Biotech, Inc. (the “Company”) made public its corporate presentation, which is now accessible on the Company’s official website. The presentation det - Defense World
Moleculin Biotech Advances Annamycin to Phase 3 Trial - TipRanks
Moleculin Highlights Development Progress of Annamycin, Phase 2 - GuruFocus.com
Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026 – Company AnnouncementFT.com - Financial Times
Moleculin Biotech (NASDAQ:MBRX) Coverage Initiated at StockNews.com - Defense World
Bitget Wallet Expands DeSci Ecosystem Access - GlobeNewswire Inc.
Moleculin Biotech (NASDAQ:MBRX) Now Covered by StockNews.com - Defense World
Moleculin Biotech, Inc. Posts Investor Presentation on Corporate Website - Defense World
Moleculin Biotech Releases Corporate Presentation Update - TipRanks
Moleculin Biotech stock hits 52-week low at $2.11 By Investing.com - Investing.com Australia
Moleculin Biotech stock hits 52-week low at $2.11 - Investing.com
Moleculin Biotech (NASDAQ:MBRX) Coverage Initiated by Analysts at StockNews.com - Defense World
Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available - The Eastern Progress Online
Moleculin Biotech Discloses Abstract Presentation at ASH Annual MeetingHouston, TX – Moleculin Biotech, Inc. (NASDAQ: MBRX) publicly shared its recent scientific achievement through a press release distributed on December 11, 2024. The communicatio - Defense World
Phathom Pharmaceuticals Submits Citizen Petition to FDA for Correction of Orange Book Listings for VOQUEZNA Tablets - Defense World
Moleculin Participates in Virtual Investor "What this Means" Segment - The Eastern Progress Online
MBRXMoleculin Biotech, Inc. Latest Stock News & Market Updates - StockTitan
What's Going On With Moleculin Biotech Shares Wednesday?Moleculin Biotech (NASDAQ:MBRX) - Benzinga
Moleculin Biotech Advances Annamycin for AML Treatment - TipRanks
Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model - PR Newswire
Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML) - The Eastern Progress Online
Moleculin to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar - The Eastern Progress Online
Moleculin Receives Institutional Review Board Approval for MIRAC - GuruFocus.com
Moleculin to Present at Two Upcoming Investor Conferences - GuruFocus.com
Moleculin Reports Third Quarter 2024 Financial Results and Provi - GuruFocus.com
Moleculin Appoints Leading Expert in Pancreatic Cancer to its Sc - GuruFocus.com
Financial Comparison: Moleculin Biotech (NASDAQ:MBRX) & RedHill Biopharma (NASDAQ:RDHL) - Defense World
Moleculin Biotech Corporate Presentation Posted on Company WebsiteOn November 18, 2024, Moleculin Biotech, Inc. made public a corporate presentation on its official website. This presentation, identified as Exhibit 99.1 in the Current Report on Form - Defense World
What is Roth Capital’s Forecast for MBRX Q1 Earnings? - Defense World
Moleculin Biotech Unveils New Corporate Presentation - TipRanks
New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML - PR Newswire
Moleculin Biotech Amends Clinical Trial Protocol for Phase 3 Trial - Defense World
Armistice Capital, LLC Expands Portfolio with Moleculin Biotech Inc Acquisition - GuruFocus.com
Moleculin (MBRX) Stock Jumps On Accelerated Clinical Trial News - Stocks Telegraph
Moleculin Biotech, Inc. Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia Pivotal Trial to H2 2025 - Marketscreener.com
Moleculin Biotech advances Annamycin AML trial protocol - Investing.com
Moleculin Biotech Accelerates Annamycin Phase 3 Trial - TipRanks
Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025 - PR Newswire
Maxim Group Has Lowered Expectations for Moleculin Biotech (NASDAQ:MBRX) Stock Price - Defense World
Moleculin Biotech Reports Financial Highlights and Future Plans - Yahoo Finance
Earnings call: Moleculin Biotech optimistic on Annamycin's trial - Investing.com
Moleculin gets IRB nod for Phase 3 AML trial - Investing.com India
Moleculin Biotech, Inc. (NASDAQ:MBRX) Q3 2024 Earnings Call Transcript - Insider Monkey
Moleculin gets IRB nod for Phase 3 AML trial By Investing.com - Investing.com Nigeria
Earnings call: Moleculin Biotech optimistic on Annamycin's trial By Investing.com - Investing.com Australia
Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update - PR Newswire
Moleculin Biotech Inc. (MBRX) Quarterly 10-Q Report - Quartz
Moleculin Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Moleculin Biotech Inc Azioni (MBRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.65%
4.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):